Core Viewpoint - Altria Group, Inc. is expected to report a decline in revenues for Q2 2025, while earnings are projected to show growth compared to the previous year [1][9]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for Q2 revenues is $5.2 billion, reflecting a 1.7% decrease from the same period last year [1]. - The consensus estimate for earnings per share (EPS) has increased to $1.37, indicating a 4.6% growth year-over-year [1][9]. Earnings Performance and Predictions - Altria has a trailing four-quarter average earnings surprise of 1.3%, with the last quarter's earnings exceeding the Zacks Consensus Estimate by 5.1% [2]. - The company currently has an Earnings ESP of +1.03% and a Zacks Rank of 3 (Hold), suggesting a potential earnings beat [4][3]. Factors Influencing Q2 Earnings - Regulatory pressures, particularly the ITC's exclusion order on NJOY ACE, have negatively impacted Altria's smoke-free product portfolio [5]. - The cigarette business is facing volume pressures due to consumer downtrading and competition from illicit flavored disposable vapes [5]. - Despite these challenges, Altria's strong pricing power and cost control measures are expected to support profitability [6][7]. Stock Performance - Over the past three months, Altria's stock has increased by 2.6%, slightly below the Zacks Tobacco industry's growth of 2.7% and significantly trailing the S&P 500's 15.5% rise [8]. - Altria's stock performance has outpaced Philip Morris International, which declined by 6.8%, but underperformed Turning Point Brands and British American Tobacco [8]. Valuation Analysis - Altria shares are trading at a forward 12-month price-to-earnings (P/E) ratio of 10.96, below the industry average of 14.48, indicating attractive value for investors [11]. - Compared to key competitors, Altria's P/E ratio is significantly lower than Philip Morris International (20.11) and Turning Point Brands (21.54), while being comparable to British American Tobacco (10.94) [13]. Investment Outlook - Altria faces a mixed backdrop with regulatory challenges and volume pressures, but resilient pricing power and disciplined cost control may provide stability [14]. - Investors may consider holding positions or selectively adding to their investments, while monitoring management's updates on product pipeline and strategic execution [14].

Core Insights - The tobacco sector presents two main investment options: Altria Group, Inc. and Philip Morris International Inc., each with distinct market strategies and growth trajectories towards a smoke-free future [1][2] Altria Group, Inc. - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into alternatives like NJOY and oral nicotine pouches [2] - The company achieved a 10.8% net price realization in smokeable products in Q1 2025, contributing to a 2.7% increase in adjusted operating income [3][9] - Altria's oral nicotine pouch brand, on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [4][9] - Despite setbacks in the e-vapor category, Altria is refining its product pipeline and advocating for regulatory reforms to combat the rise of illicit disposable e-vapor products, which account for over 60% of the U.S. market [5] - The cigarette industry faces challenges, with shipment volumes declining due to macroeconomic pressures and the growth of illegal e-vapor products, impacting low-income smokers [6] Philip Morris International Inc. - Philip Morris is advancing its transformation strategy with a strong smoke-free portfolio, including IQOS, ZYN, and VEEV, and has approximately 41.5 million adult users by Q2 2025 [7][9] - IQOS is the primary driver of growth, with accelerated adoption in key markets supported by commercial initiatives and product innovations [8][10] - The company offers smoke-free products in 97 markets, with nearly half providing multiple product categories, enhancing its global reach [10] - Philip Morris faces challenges such as currency volatility and increasing regulatory risks, particularly regarding nicotine pouch marketing [11] Financial Performance and Valuation - Altria's forward P/E ratio is 10.96, appealing to income-focused investors, while Philip Morris has a higher multiple of 20.12, reflecting its global presence and momentum in smoke-free products [15] - Over the past month, Altria gained 2.1%, while Philip Morris dropped 11.6%, underperforming the S&P 500's 3.4% rise [14] Conclusion - Philip Morris is better positioned for long-term growth with its aggressive pivot towards a smoke-free future and strong global traction, while Altria's focus on domestic stability and pricing strength supports income-focused investors but faces more headwinds [16]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. Wha ...

Core Viewpoint - Traditional cigarette sales are declining, but Philip Morris International is offsetting this with strong growth in its newer nicotine products, particularly the Zyn brand and heated tobacco units [1][10]. Group 1: Sales Performance - Zyn shipments in the U.S. increased by 40% to 190 million cans in Q2, with retail sales volumes growing by 26% in the quarter and 36% in June [1]. - Outside the U.S. and Nordic countries, Zyn shipments more than doubled, now available in 44 markets, with overall oral product shipments climbing 23.8% [2]. - Sales volumes of heated tobacco units (HTUs), including the Iqos system, rose nearly 9.2% to 38.8 billion units, with in-market sales increasing by 11.4% [4]. - E-vapor product Veev saw shipment growth more than double, driven by pod growth in Europe, now in 42 markets and holding the No. 1 market share in six European markets [5]. Group 2: Financial Metrics - Organic revenue rose 6.8% year over year to $10.1 billion, with adjusted earnings per share (EPS) climbing 20% to $1.91 [6]. - Traditional cigarette volumes fell by 1.5% to 155.2 billion units, but segment organic revenue grew 2% to $6 billion, and gross profits increased by 5% to $4 billion due to price hikes [5]. - Management maintained its full-year guidance for organic revenue growth at 6% to 8% while raising adjusted EPS guidance to $7.43 to $7.56 [9]. Group 3: Market Outlook - The company expects a 3% to 4% decline in traditional cigarette volumes due to supply chain issues in Turkey and competition from illicit cigarettes in Indonesia [7][8]. - Despite the forecast for steeper declines in cigarette sales volumes, the smoke-free portfolio, particularly Zyn and Iqos, continues to show strong growth and better unit economics [10][11]. - The stock is viewed as undervalued with a forward price-to-earnings (P/E) ratio under 22 and a PEG ratio below 0.35, indicating potential for growth [12]. Group 4: Investment Considerations - The current share price offers a forward dividend yield of 3.3%, which, while lower than some competitors, positions the company as a unique growth stock in a defensive industry [13]. - The dip in stock price presents a potential buying opportunity for long-term investors [13].

Core Insights - Philip Morris International (PM) raised its 2025 earnings per share (EPS) guidance to $7.43-$7.56, reflecting strong second-quarter performance driven by smoke-free products, indicating a year-over-year growth of 13-15% [1][10] Financial Performance - In Q2 2025, smoke-free net revenues increased by 15.2% year over year, with gross profit for this segment rising over 23%, contributing 41% to total net revenues and 42% to gross profit [2][10] - Adjusted operating income grew by 16.1% in the quarter, outpacing revenue gains, attributed to strong pricing, improved scale efficiencies, and a favorable category mix towards higher-margin smoke-free products [4][10] Product Performance - The multi-category smoke-free platform showed broad-based growth, with IQOS heated tobacco units' adjusted in-market sales rising by 11.4%, supported by global expansion and recovery in European markets [3] - ZYN experienced a significant rebound, with U.S. consumer offtake increasing by 26% in the quarter and 36% in June, driven by better in-store availability and renewed commercial activity [3] Market Strategy - The raised EPS guidance indicates management's confidence in the sustainability of recent smoke-free category growth, suggesting that the multi-category strategy is gaining traction faster than anticipated [5] Competitive Landscape - Altria Group's "on!" nicotine pouch brand saw an 18% increase in shipment volume, while Turning Point Brands reported nearly tenfold growth in modern oral nicotine pouch sales, contributing $22.3 million in revenues [6][7][8] Valuation Metrics - Philip Morris shares have declined by 10.2% in the past month, compared to the industry's decline of 2.2% [9] - The company trades at a forward price-to-earnings ratio of 20.16X, higher than the industry's average of 14.67X [12] - The Zacks Consensus Estimate for PM's earnings implies year-over-year growth of 14.2% for 2025 and 11.9% for 2026 [13]

Core Viewpoint - Analysts forecast Altria (MO) to report quarterly earnings of $1.37 per share, reflecting a year-over-year increase of 4.6%, while revenues are expected to be $5.19 billion, a decrease of 1.6% compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been adjusted downward by 0.5% over the past 30 days, indicating a reassessment by covering analysts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3] Revenue Projections - Analysts estimate 'Net revenue- All Other/ Financial Services' to reach $14.00 million, a significant increase of 366.7% from the prior-year quarter [5] - 'Revenues net of excise taxes- Oral tobacco products' are projected at $701.72 million, showing a 2.1% increase year-over-year [5] - 'Revenues net of excise taxes- Smokeable Products' are expected to be $4.43 billion, indicating a decline of 3.3% compared to the previous year [6] Operating Income Estimates - The average prediction for 'Operating Income (Loss)/ Reported OCI- Oral tobacco products' is $459.60 million, compared to $97.00 million reported in the same quarter last year [6] - 'Adjusted OCI- Smokeable Products' is anticipated to reach $2.86 billion, slightly up from $2.83 billion reported in the same quarter of the previous year [7] Market Performance - Altria shares have returned +1.4% over the past month, underperforming compared to the Zacks S&P 500 composite's +4.6% change [7] - Altria holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [7]

Company Overview and Strategic Direction - Philip Morris International is a leading global producer of tobacco and nicotine products, operating in approximately 170 markets with well-known brands such as Marlboro, Parliament, IQOS, ZYN, and VEEV [2] - The company is transitioning from traditional combustible cigarettes to smoke-free alternatives, including heated tobacco devices, oral nicotine pouches, and electronic vapor products [3] Quarterly Performance Highlights - In Q2 2025, adjusted earnings per share were $1.91, exceeding the estimate of $1.86 by 2.7%, while GAAP revenue was $10.1 billion, falling short by 2.1% [1] - Smoke-free products accounted for 41% of net revenue, an increase of 2.9 percentage points year-over-year, with gross profit from these products exceeding 42% of total gross profit [4] - Shipments of smoke-free products rose by 11.8%, with net revenue in this segment increasing by 15.2% and gross profit up by 23.3% [4] Product Performance - IQOS generated over $3 billion in net revenue, holding a 76% share of the global heat-not-burn category, with sales volumes in Europe growing by 9.1% and in Japan by 7.8% [5] - ZYN pouches saw a global shipment volume increase of 26.5%, with U.S. shipments rising over 40% to 190 million cans [6] - VEEV e-vapor product volumes more than doubled, achieving top market positions in six European countries [6] Traditional Cigarette Segment - Traditional cigarette volumes declined by 1.5%, but revenue for this segment grew by 2.1% due to strong pricing [7] - Marketing, Administration, and Research Costs increased by 16.0% compared to the previous year [7] Regional Performance - Europe's organic revenue rose by 7.3%, driven by smoke-free growth, while the Americas experienced a 17% increase in organic net revenues, primarily from oral nicotine [8] - The European market faced a 1.7% decline in shipment volume, mainly due to cigarette declines in specific countries [8] Future Outlook - The company raised its full-year adjusted diluted EPS guidance to $7.43, reflecting an 11.5% to 13.5% growth from last year's adjusted EPS of $6.57 [10] - Organic net revenue growth is forecasted at 6-8%, with smoke-free product volumes expected to grow by 12-14% and cigarette volumes projected to decline by about 2% [10] - Capital expenditure guidance is set at $1.6 billion, primarily for smoke-free product scale-up, with operating cash flow expected around $11.5 billion [10]

Group 1 - The article discusses a previous analysis on Altria Group, Inc. (NYSE: MO) stock, highlighting that Wall Street may have overlooked significant factors affecting the stock's performance [1] - Sensor Unlimited, an economist with a PhD, has been covering various financial markets including the mortgage and banking sectors for the past decade [2] - The focus of Sensor Unlimited's work includes asset allocation and ETFs related to the overall market, bonds, banking, and housing markets [2]

Core Viewpoint - Altria is expected to report a year-over-year increase in earnings despite a decline in revenues for the quarter ended June 2025, with the consensus outlook indicating potential impacts on its stock price based on actual results compared to estimates [1][3]. Earnings Expectations - The consensus estimate for Altria's quarterly earnings is $1.37 per share, reflecting a year-over-year increase of +4.6%, while revenues are projected to be $5.19 billion, down 1.7% from the previous year [3]. - A positive earnings surprise could lead to a stock price increase, while a miss could result in a decline [2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.51%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Altria is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.03%, suggesting a bullish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Altria currently holds a Zacks Rank of 3, which, combined with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Altria exceeded the expected earnings of $1.17 per share by delivering $1.23, resulting in a surprise of +5.13% [13]. - Over the past four quarters, Altria has beaten consensus EPS estimates three times [14]. Conclusion - Altria is positioned as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance beyond just earnings results [17].

Core Viewpoint - Philip Morris (PM) is experiencing significant selling pressure, with a 10.4% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better-than-previously predicted earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold conditions, with a reading below 30 typically indicating that a stock is oversold [2]. - PM's current RSI reading is 27.52, suggesting that the heavy selling may be exhausting itself, indicating a potential bounce back towards equilibrium in supply and demand [5]. - The RSI helps investors identify entry opportunities when a stock is undervalued due to unwarranted selling pressure [3]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that PM will report better earnings, leading to a 0.5% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions is typically associated with price appreciation in the near term, further supporting the potential for a rebound in PM's stock price [7]. - PM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8].